Altimmune begins multinational phase 2 clinical trial of heptcelltm, a novel immunotherapeutic for the treatment of chronic hepatitis b

Gaithersburg, md., dec. 30, 2020 (globe newswire) -- altimmune, inc. (nasdaq: alt), a clinical-stage biopharmaceutical company, today announced that it has enrolled the first patient in its multinational phase 2 clinical trial of heptcell, a novel peptide-based immunotherapeutic under development for treatment of chronic hepatitis b (chb).
ALT Ratings Summary
ALT Quant Ranking